February 15, 2021
January 27, 2021
Riluzole is an FDA-approved drug, currently used to treat amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease) and is currently in a Phase II clinical trial for the treatment of mild Alzheimer’s disease (AD) (Clinical Trial #NCT01703117).
October 30, 2020
According to the National Institute on Aging there are more than 41 million licensed drivers age 65 and older on the roads, up from 26 million 20 years ago. As a person ages, changes in health-including problems with vision, hearing, and reflexes-may affect driving skills. The risk of being inj
October 19, 2020
Neurons are the cells responsible for communicating important information to different areas of the brain.
October 19, 2020
At SIU Medicine’s Center for Alzheimer’s Disease and Related Disorders, we are committed to the care for our patients and their families – especially during the pandemic.
September 10, 2020
Medical researchers at SIU School of Medicine’s Neuroscience Institute are studying how the novel coronavirus may accelerate the progression of Alzheimer’s disease. Their data could help identify patients that are more susceptible to the disease’s cognitive and physical decline.
The Center for Alzheimer's Disease and Related Disorders at SIU Medicine received a grant from the King’s Daughters Organization for the fourth year in a row
September 4, 2020
The King’s Daughters Organization awarded the Center for Alzheimer’s Disease and Related Disorders (CADRD) a grant for $7,724 to support our Minds in Motion and Opening Minds Through Art (OMA) Beyond the Medical Center programs through 2021.
August 31, 2020
In August 2020, Erin Hascup PhD, Alzheimer's Center Director, and Kevin Hascup PhD, Assistant Professor published "Toward refining Alzhiemer's disease into overlapping subgroups".
February 6, 2020
February 4, 2020 WTAX, Erin Hascup, Ph.D., Director Center for Alzheimer's Disease and Related Disorders. Ask the Experts with Memorial Health Systems, Topic: Alzheimer's Disease.